Cantor Fitzgerald Reiterates "Overweight" Rating for Organogenesis (NASDAQ:ORGO)

Cantor Fitzgerald reiterated their overweight rating on shares of Organogenesis (NASDAQ:ORGO - Free Report) in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a $7.00 price target on the stock.

Organogenesis Stock Performance

ORGO stock traded up $0.44 during trading on Tuesday, reaching $4.47. The company had a trading volume of 1,029,364 shares, compared to its average volume of 1,144,383. Organogenesis has a twelve month low of $2.28 and a twelve month high of $6.71. The company has a market cap of $567.02 million, a price-to-earnings ratio of -26.29 and a beta of 1.70. The firm has a 50-day simple moving average of $3.46 and a 200-day simple moving average of $3.88.

Organogenesis (NASDAQ:ORGO - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.17). The company had revenue of $86.69 million for the quarter, compared to analysts' expectations of $90.77 million. Organogenesis had a negative net margin of 3.46% and a negative return on equity of 4.00%. Sell-side analysts expect that Organogenesis will post -0.07 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Lori Freedman bought 9,022 shares of the business's stock in a transaction dated Friday, June 6th. The stock was purchased at an average cost of $2.99 per share, with a total value of $26,975.78. Following the acquisition, the insider directly owned 846,459 shares in the company, valued at $2,530,912.41. This trade represents a 1.08% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders bought 252,264 shares of company stock worth $725,732 over the last quarter. 33.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Organogenesis

Institutional investors and hedge funds have recently modified their holdings of the business. Soleus Capital Management L.P. grew its stake in Organogenesis by 5.4% in the 4th quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company's stock valued at $39,952,000 after acquiring an additional 645,000 shares during the period. Vanguard Group Inc. lifted its holdings in Organogenesis by 23.4% during the first quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company's stock valued at $19,144,000 after purchasing an additional 841,618 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of Organogenesis by 748.1% in the second quarter. Assenagon Asset Management S.A. now owns 2,857,904 shares of the company's stock valued at $10,460,000 after purchasing an additional 2,520,941 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Organogenesis by 18.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company's stock worth $8,925,000 after purchasing an additional 442,772 shares in the last quarter. Finally, Driehaus Capital Management LLC purchased a new stake in shares of Organogenesis during the first quarter worth about $7,756,000. Hedge funds and other institutional investors own 49.57% of the company's stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.